juvenile idiopathic arthritis
Â
Tocilizumab in polyarticular juvenile idiopathic arthritis: a cost-utility model for the United Kingdom
Value in Health. 2013;16(7):A564
Authors
Chang S, Sawyer L, Dejonckheere F, van Suijlekom-Smit LW, Anink J, Diamantopoulos A
Process
An individual sampling model was developed to reflect the health care system and treatment pathway in the UK
Utility data were derived from a large national database
Costs were calculated from National Health Service reference costs and Personal Social Services perspective
Efficacy inputs were derived from an indirect treatment comparison conducted by Symmetron
Publications in other disease areas
Atrial fibrillation
Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke
Cancer
Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom
Idiopathic pulmonary fibrosis
The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review
Psoriasis
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis
Rheumatoid arthritis
Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK
Venous thromboembolism
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective